Skip to main content
. 2020 Apr 27;11:315. doi: 10.3389/fpsyt.2020.00315

Figure 2.

Figure 2

Main findings regarding the therapeutic potential of the functional manipulation of the endocannabinoid system (ECS) components by pharmacological and genetic approaches in anxiety, depression, schizophrenia, and post-traumatic stress disorder (PTSD). CB1r, cannabinoid receptor 1; CB2r, cannabinoid receptor 2; AEA, anandamide; 2-AG, 2-arachidonoylglycerol; FAAH, fatty acid amide hydrolase; MAGL, monoacylglycerol lipase; 5-HT, serotonin; NA, noradrenaline; DA, dopamine; AcH: acetylcholine; GABA, gamma-aminobutyric acid; Glu, glutamate; HPA axis, Hypothalamus–Pituitary–Adrenal axis; *, chronic treatment.